Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention

Canadian Family Physician

Volumn 59, Issue 1, 2013, Pages 55-61

  Kolber, Michael ^a   Sharif, Nadder ^b   Marceau, Raelene ^b   Szafran, Olga ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; FAMILY MEDICINE; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PREVALENCE; PRIMARY PREVENTION; QUESTIONNAIRE; SECONDARY PREVENTION; SELF REPORT;

AGED; AGED, 80 AND OVER; ALBERTA; AMBULATORY CARE FACILITIES; ASPIRIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RURAL POPULATION; SECONDARY PREVENTION; SELF REPORT; URBAN POPULATION;

EID: 84873836075     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;30(1):74-7.
2. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med 2007;32(5):403-7.
3. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008;121(1):43-9.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86. Erratum in: BMJ 2002;324(7330):141.
5. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295(3):306-13. Erratum in: JAMA 2006;295(17):2002.
6. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352(13):1293-304. Epub 2005 Mar 7.
7. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-60.
8. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150(6):405-10.
9. Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of lowdose aspirin. Am J Gastroenterol 2000;95(9):2218-24.
10. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. DOI:10.1136/bmj.b4531.
11. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26(12):3264-72.
12. Walsh M, Spurling G. Aspirin in type 2 diabetes: is there any evidence base? BMJ 2008;337:a1902. DOI:10.1136/bmj.a1902.
13. Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev 2004;(3):003186.
14. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134-41. Epub 2008 Nov 9.
15. Statistics Canada [website]. 2006 Community profiles. Peace River, Alberta. Catalogue no. 92-591-XWE. Ottawa, ON: Statistics Canada; 2010. Available from: www12.statcan.gc.ca/census-recensement/2006/dp-pd/prof/92-591/ details/page.cfm? Lang=E&Geo1=CSD&Code1=4819038&Geo2=PR&Code2= 48&Data=Count&SearchText=peace river&SearchType=Begins&SearchPR= 48&B1=All&Custom=. Accessed 2011 Jun 7.
16. Centers for Disease Control and Prevention. 2003 Behavioral risk factor surveillance system state questionnaire. Atlanta, GA: Centers for Disease Control and Prevention; 2002. Available from: www.cdc.gov/brfss/questionnaires/ pdf-ques/2003brfss.pdf. Accessed 2011 Jul 27.
17. Statistics Canada [website]. Canada's population estimates. Population by sex and age group. Ottawa, ON: Statistics Canada; 2010. Available from: www.statcan.gc.ca/daily-quotidien/100929/dq100929b-eng.htm. Accessed 2011 Jun 7.
18. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996;124(4):414-21.
19. Frijling BD, Lobo CM, Keus IM, Jenks KM, Akkermans RP, Hulscher ME, et al. Perceptions of cardiovascular risk among patients with hypertension or diabetes. Patient Educ Couns 2004;52(1):47-53.
20. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321(3):129-35.
21. Patrono C, Baigent C, Hirsh J, Roth G. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133(6 Suppl):199S-233S.
22. Tsuyuki RT, Koshman S, Pearson G. Guideline for management of modifiable risk factors in adults at high risk for cardiovascular events. Edmonton, AB: Toward Optimized Practice; 2009. Available from: www.topalbertadoctors.org/cpgs. php?sid=11&cpg-cats=37. Accessed 2011 Jun 7.
23. Guidelines & Protocols Advisory Committee. Cardiovascular disease- primary prevention. Vancouver, BC: British Columbia Medical Association; 2008. Available from: www.bcguidelines.ca/pdf/cvd.pdf. Accessed 2011 Jun 7.
24. Public Health Agency of Canada. Tracking heart disease and stroke in Canada. Ottawa, ON: Public Health Agency of Canada; 2009. Available from: www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf. Accessed 2011 Jun 7.
25. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin- what's the risk? Aliment Pharmacol Ther 2006;24(6):897-908.
26. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321(7270):1183-7.
27. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329(7456):15-9.
28. Allan GM, Kolber MR. ASA in primary prevention: do the benefits outweigh risks? Edmonton, AB: Alberta College of Family Physicians; 2009. Available from: www.acfp.ca/docs10/2010-08-09%20ASA%20Primary%20Prevention.pdf. Accessed 2011 Jul 27.
29. Kolber MR, Wong CWK. Acetylsalicylic acid (ASA) to prevent colorectal cancer? Edmonton, AB: Alberta College of Family Physicians; 2011. Available from: www.acfp.ca/docs11/TFP47ASAColorectalCancer.pdf. Accessed 2011 Jul 27.
30. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171(10):1189-92.
31. Alter DA, Khaykin Y, Austin PC, Tu JV, Hux JE. Processes and outcomes of care for diabetic acute myocardial infarction patients in Ontario: do physicians undertreat? Diabetes Care 2003;26(5):1427-34.
32. Grimaldi-Bensouda L, Rossignol M, Aubrun E, El Kerri N, Benichou J, Abenhaim L, et al. Agreement between patients' self-report and physicians' prescriptions on cardiovascular drug exposure: the PGRx database experience. Pharmacoepidemiol Drug Saf 2010;19(6):591-5. Erratum in: Pharmacoepidemiol Drug Saf 2010;19(11):1209.
33. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57(10):1096-103.